loading
Schlusskurs vom Vortag:
$20.09
Offen:
$19.97
24-Stunden-Volumen:
75,777
Relative Volume:
0.75
Marktkapitalisierung:
$253.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.48M
KGV:
-19.47
EPS:
-1.04
Netto-Cashflow:
$-28.71M
1W Leistung:
+10.60%
1M Leistung:
+48.13%
6M Leistung:
+65.31%
1J Leistung:
-13.87%
1-Tages-Spanne:
Value
$19.75
$21.41
1-Wochen-Bereich:
Value
$17.82
$21.45
52-Wochen-Spanne:
Value
$4.90
$25.97

Forte Biosciences Inc Stock (FBRX) Company Profile

Name
Firmenname
Forte Biosciences Inc
Name
Telefon
(310) 618-6994
Name
Adresse
3060 PEGASUS PARK DRIVE, DALLAS, CA
Name
Mitarbeiter
16
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
FBRX's Discussions on Twitter

Vergleichen Sie FBRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FBRX
Forte Biosciences Inc
20.25 251.67M 0 -31.48M -28.71M -1.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.64 110.88B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
726.21 72.79B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
890.11 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
404.46 54.85B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
189.85 41.41B 447.02M -1.18B -906.14M -6.1812

Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-11-25 Eingeleitet Evercore ISI Outperform
2025-08-18 Eingeleitet Guggenheim Buy
2025-01-21 Eingeleitet TD Cowen Buy
2024-04-08 Hochstufung Ladenburg Thalmann Neutral → Buy
2021-09-20 Hochstufung Chardan Capital Markets Sell → Buy
2021-09-03 Herabstufung B. Riley Securities Buy → Neutral
2021-09-03 Herabstufung Chardan Capital Markets Buy → Sell
2021-09-03 Herabstufung Ladenburg Thalmann Buy → Neutral
2021-09-03 Herabstufung Truist Buy → Hold
2021-05-14 Eingeleitet B. Riley Securities Buy
2021-03-26 Eingeleitet Citigroup Buy
2020-08-28 Hochstufung Chardan Capital Markets Neutral → Buy
2020-08-25 Eingeleitet Truist Buy
Alle ansehen

Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten

pulisher
Dec 10, 2025

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times

Dec 10, 2025
pulisher
Dec 06, 2025

Forte Biosciences (FBRX) Stock Analysis Report | Financials & Insights - Benzinga

Dec 06, 2025
pulisher
Dec 04, 2025

What downside risks could hit Forte Biosciences Inc. (37T) stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Recent Research Analysts’ Ratings Changes for Forte Biosciences (FBRX) - Defense World

Dec 04, 2025
pulisher
Dec 03, 2025

Forte Biosciences initiated with an Outperform at Evercore ISI - MSN

Dec 03, 2025
pulisher
Dec 03, 2025

What analyst consensus implies for Forte Biosciences Inc. (37T) stockWatch List & Trade Opportunity Analysis Reports - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

Is Forte Biosciences Inc. stock a top pick in earnings seasonJuly 2025 Update & Trade Opportunity Analysis - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

How forex fluctuations impact Forte Biosciences Inc. (37T) stockTrade Ideas & Weekly Hot Stock Watchlists - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Is Forte Biosciences Inc. stock attractive for passive investors2025 Market WrapUp & High Accuracy Trade Signal Alerts - Newser

Dec 02, 2025
pulisher
Nov 30, 2025

Forte Biosciences Inc. (FBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 30, 2025
pulisher
Nov 30, 2025

18,856 Shares in Forte Biosciences, Inc. $FBRX Purchased by Envestnet Asset Management Inc. - MarketBeat

Nov 30, 2025
pulisher
Nov 29, 2025

Forte Biosciences, Inc. (FBRX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Nov 29, 2025
pulisher
Nov 28, 2025

Forte Biosciences (NASDAQ:FBRX) Coverage Initiated by Analysts at Evercore ISI - MarketBeat

Nov 28, 2025
pulisher
Nov 28, 2025

Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - MarketBeat

Nov 28, 2025
pulisher
Nov 28, 2025

Forte Biosciences (NASDAQ:FBRX) Earns Outperform Rating from Analysts at Evercore ISI - Defense World

Nov 28, 2025
pulisher
Nov 28, 2025

Analysts Set Forte Biosciences, Inc. (NASDAQ:FBRX) PT at $67.00 - Defense World

Nov 28, 2025
pulisher
Nov 27, 2025

Why Forte Biosciences Inc. stock could benefit from AI revolution2025 Year in Review & AI Enhanced Market Trend Forecasts - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 27, 2025

How does Forte Biosciences Inc (FBRX) change from a tortoise to a hare? - Setenews

Nov 27, 2025
pulisher
Nov 26, 2025

Forte Biosciences, Inc. (NASDAQ:FBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 26, 2025
pulisher
Nov 25, 2025

Evercore ISI initiates coverage on Forte Biosciences stock with Outperform rating - Investing.com Australia

Nov 25, 2025
pulisher
Nov 25, 2025

Vitiligo Pipeline Advancements Report 2025: DelveInsight Highlights Emerging Therapeutics Reshaping the Treatment Landscape - The Globe and Mail

Nov 25, 2025
pulisher
Nov 25, 2025

FBRX: Evercore ISI Group Initiates Coverage with Outperform Rati - GuruFocus

Nov 25, 2025
pulisher
Nov 24, 2025

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - marketscreener.com

Nov 24, 2025
pulisher
Nov 24, 2025

Forte Biosciences (NASDAQ: FBRX) approves Nasdaq Rule 5635(c)(4) inducement option grant - Stock Titan

Nov 24, 2025
pulisher
Nov 23, 2025

Is Forte Biosciences Inc a good long term investmentHead and Shoulders Patterns & Small Investment Big Gains - earlytimes.in

Nov 23, 2025
pulisher
Nov 22, 2025

What analysts say about Forte Biosciences Inc stockVolume Spike Alerts & Affordable Market Trading - earlytimes.in

Nov 22, 2025
pulisher
Nov 21, 2025

Why Forte Biosciences Inc. (37T) stock is a strong buy callQuarterly Earnings Report & Technical Pattern Recognition Alerts - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

What is Chardan Capital’s Estimate for FBRX FY2025 Earnings? - Defense World

Nov 21, 2025
pulisher
Nov 20, 2025

Why Forte Biosciences Inc. (37T) stock appears on watchlists2025 Support & Resistance & Safe Entry Zone Tips - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will Forte Biosciences Inc. stock gain from lower inflationJuly 2025 Intraday Action & AI Driven Stock Movement Reports - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Can Forte Biosciences Inc. (37T) stock deliver strong annual returnsJuly 2025 Setups & Low Risk Profit Maximizing Plans - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Is Forte Biosciences Inc. (37T) stock vulnerable to rate hikes2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Will Forte Biosciences Inc. (37T) stock profit from AI boomJuly 2025 Spike Watch & Free Reliable Trade Execution Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Published on: 2025-11-19 14:11:29 - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What drives Forte Biosciences Inc stock priceMid Cap Growth Trends & Budget Friendly Growth Tips - earlytimes.in

Nov 19, 2025
pulisher
Nov 19, 2025

Why Forte Biosciences Inc. stock is in analyst buy zoneMarket Risk Summary & Technical Buy Zone Confirmations - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Developing predictive dashboards with Forte Biosciences Inc. data2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Chardan Capital Reaffirms “Buy” Rating for Forte Biosciences (NASDAQ:FBRX) - Defense World

Nov 19, 2025
pulisher
Nov 19, 2025

How analysts revise price targets for Forte Biosciences Inc. (37T) stock2025 Market Trends & Scalable Portfolio Growth Methods - newser.com

Nov 19, 2025

Finanzdaten der Forte Biosciences Inc-Aktie (FBRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.26
price up icon 0.45%
$95.17
price up icon 0.01%
$31.24
price up icon 1.00%
$95.73
price down icon 0.12%
biotechnology ONC
$322.68
price up icon 1.25%
$189.85
price down icon 2.22%
Kapitalisierung:     |  Volumen (24h):